Pfizer wins Metsera with $10 billion offer as Novo Nordisk drops out

Pfizer will buy the obesity drug developer Metsera for up to $86.25 a share, or more than $10 billion, after rival Novo Nordisk dropped out of the bidding ^[1][4]. Metsera's board accepted Pfizer's sweetened offer late Friday, Nov. 7, and Novo said the next day it would not raise its own bid ^[1][3].

The price breaks into $65.60 a share in cash, plus a contingent value right that could pay up to $20.65 more per share if certain milestones are reached ^[1][4]. Metsera said the total was a 3.69% premium to its Friday closing price ^[1]. The board unanimously recommends that shareholders approve the deal at a Nov. 13 meeting, and the companies expect to close soon after; the merger has already received FTC clearance ^[4].

The fight started cheaper. Pfizer's first offer, announced Sept. 22, valued Metsera at $4.9 billion — $47.50 a share upfront plus a CVR of up to $22.50 ^[4][6]. On Oct. 30, Novo came in unsolicited with a two-step proposal worth up to about $9.1 billion, or $77.75 a share, structured to move roughly half of Metsera's equity and most of the cash to shareholders before any antitrust review ^[6]. Pfizer sued in two courts, arguing the structure violated antitrust law; a Delaware judge declined to block Novo's deal, and Novo raised its bid to about $10 billion ^[4].

The end came down to regulatory risk rather than price. Metsera said Novo's proposal carried "unacceptably high legal and regulatory risks," pointing to an FTC letter stating the deal ran the risk of violating U.S. antitrust laws and to a call from the agency about the risks ^[1][3][4]. A legal analysis of the contest concluded that the final Pfizer and Novo proposals were identical in amount and composition, differing in structure, timing and the odds that each would close ^[6]. Novo said it believed its structure was "compliant with antitrust laws" and that stepping aside was "consistent with its commitment to financial discipline and shareholder value" ^[1][4]. Citing its own obesity pipeline, Novo said it "will not increase its offer to acquire Metsera" ^[1][3].

Metsera's shares gained nearly 60% from just before Novo's bid through Friday's close, lifting its market value to $8.75 billion ^[1]. The stock priced at $18 a share when the company went public in January ^[4][6].

Why it matters for patients

Nothing in this deal changes what is available at a pharmacy today. Metsera's lead candidates — MET-097i, an injectable GLP-1, and MET-233i, which mimics the hormone amylin — are experimental and years from reaching the market ^[1][4]. Both remain unproven; Metsera currently loses money, and analysts expect additional losses while the drugs are still in development ^[1]. The most advanced of the company's treatments might require monthly injections rather than the weekly shots used with Novo's Wegovy, a semaglutide, and Eli Lilly's Zepbound, a tirzepatide ^[4].

Sales estimates are doing a lot of work in the $10 billion price. Leerink Partners projects $5 billion in combined peak sales for the two drugs ^[1]. Bernstein analyst Courtney Breen said the price rests on optimistic assumptions, estimating Pfizer would need to assume $11 billion in revenue by 2040 — nearly double Metsera's current projections — and pointing to growing skepticism about long-term GLP-1 pricing that could compress margins ^[1]. Those are forecasts, not results from a finished product.

The antitrust fight also shows how concentrated the obesity market has become. Novo and Eli Lilly, which sell competing GLP-1 medicines, were the two companies positioned to buy Metsera ^[4]. The FTC's letter concerned the risk that a Novo deal would violate antitrust law, not Metsera's science ^[1][4].

What happens next

Metsera shareholders vote on Nov. 13 ^[4]. Pfizer expects the merger to close shortly after that, and the deal has already cleared the FTC ^[4]. The specific milestones tied to the new contingent payments have not been disclosed, and no timeline for late-stage trials or a possible approval has been reported.